Document Detail


Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload.
MedLine Citation:
PMID:  15687129     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Although aldosterone, acting via mineralocorticoid receptors, causes left ventricular (LV) hypertrophy in experimental models of high-aldosterone hypertension, little is known about the role of aldosterone or mineralocorticoid receptors in mediating adverse remodeling in response to chronic pressure overload. METHODS AND RESULTS: We used the mineralocorticoid receptor-selective antagonist eplerenone (EPL) to test the role of mineralocorticoid receptors in mediating the transition from hypertrophy to failure in mice with chronic pressure overload caused by ascending aortic constriction (AAC). One week after AAC, mice were randomized to regular chow or chow containing EPL (200 mg/kg per day) for an additional 7 weeks. EPL had no significant effect on systolic blood pressure after AAC. Eight weeks after AAC, EPL treatment improved survival (94% versus 65%), attenuated the increases in LV end-diastolic (3.4+/-0.1 versus 3.7+/-0.1 mm) and end-systolic (2.0+/-0.1 versus 2.5+/-0.2 mm) dimensions, and ameliorated the decrease in fractional shortening (42+/-2% versus 34+/-4%). EPL also decreased myocardial fibrosis, myocyte apoptosis, and the ratio of matrix metalloproteinase-2/tissue inhibitor of matrix metalloproteinase-2. These beneficial effects of EPL were associated with less myocardial oxidative stress, as assessed by 3-nitrotyrosine staining, reduced expression of the adhesion molecule intercellular adhesion molecule-1, and reduced infiltration by macrophages. CONCLUSIONS: Mineralocorticoid receptors play an important role in mediating the transition from LV hypertrophy to failure with chronic pressure overload. The effects of mineralocorticoid receptor stimulation are associated with alterations in the interstitial matrix and myocyte apoptosis and may be mediated, at least in part, by oxidative stress and inflammation.
Authors:
Gabriela M Kuster; Eugene Kotlyar; Mary K Rude; Deborah A Siwik; Ronglih Liao; Wilson S Colucci; Flora Sam
Related Documents :
9928749 - Impaired baroreflex function and arterial compliance in primary aldosteronism.
17172319 - Subglottic secretion viscosity and evacuation efficiency.
19352049 - Endothelial dysfunction is related to aldosterone excess and raised blood pressure.
17606839 - The spironolactone, amiloride, losartan, and thiazide (salt) double-blind crossover tri...
965299 - Plasma renin activity, angiotensin ii, and aldosterone during intense heat stress.
212619 - Hypertension induced by adrenocortical dysfunction--hypertension in 17 alpha-hydroxylas...
635749 - The effect of a mechanical venous pump on the circulation of the feet in the presence o...
12948429 - Isolated systolic hypertension and the risk of vascular disease.
6881349 - Determinants of flow across isolated gastroduodenal junctions of cats and rabbits.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Circulation     Volume:  111     ISSN:  1524-4539     ISO Abbreviation:  Circulation     Publication Date:  2005 Feb 
Date Detail:
Created Date:  2005-02-02     Completed Date:  2005-07-11     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  United States    
Other Details:
Languages:  eng     Pagination:  420-7     Citation Subset:  AIM; IM    
Affiliation:
Cardiovascular Medicine Section, Boston University Medical Center, Boston, Mass, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Aorta
Apoptosis
Blood Pressure
Cell Size
Chronic Disease
Constriction, Pathologic / complications
Drug Evaluation, Preclinical
Fibrosis
Heart Failure / etiology,  prevention & control*
Hypertrophy, Left Ventricular / complications*,  drug therapy,  physiopathology
Intercellular Adhesion Molecule-1 / analysis
Ligation
Male
Matrix Metalloproteinases / analysis
Mice
Myocarditis / drug therapy,  etiology
Myocardium / chemistry,  pathology
Myocytes, Cardiac / pathology
Oxidative Stress / drug effects
Pressure
Random Allocation
Receptors, Mineralocorticoid / antagonists & inhibitors*,  physiology
Spironolactone / analogs & derivatives*,  pharmacology,  therapeutic use*
Tissue Inhibitor of Metalloproteinase-1 / analysis
Tissue Inhibitor of Metalloproteinase-2 / analysis
Tyrosine / analogs & derivatives*,  analysis
Grant Support
ID/Acronym/Agency:
HL20612/HL/NHLBI NIH HHS; HL61639/HL/NHLBI NIH HHS; K23 HL04423/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Receptors, Mineralocorticoid; 0/Tissue Inhibitor of Metalloproteinase-1; 0/eplerenone; 126547-89-5/Intercellular Adhesion Molecule-1; 127497-59-0/Tissue Inhibitor of Metalloproteinase-2; 3604-79-3/3-nitrotyrosine; 52-01-7/Spironolactone; 55520-40-6/Tyrosine; EC 3.4.24.-/Matrix Metalloproteinases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hyper...
Next Document:  Chest compression rates during cardiopulmonary resuscitation are suboptimal: a prospective study dur...